ClinicalTrials.gg

Non-Muscle Invasive Bladder Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 294 studies for Non-Muscle Invasive Bladder Neoplasms across more than 10 countries. 126 are recruiting or about to start. 256 of them are mainly about Non-Muscle Invasive Bladder Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Recruiting
93
Completed
79
Active, not recruiting
32
Not yet recruiting
31
Terminated
23
Status unknown
22

Phase

Phase 2
97
Phase 1
72
Phase 3
54
Phase 4
9
Early Phase 1
2

Where

United States
114
China
50
Italy
29
Spain
27
Canada
26
France
26

Who develops what

Add Non-Muscle Invasive Bladder Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 21 programs from 16 companies, 21 with this as their studies’ main aim; 7 with a live phase 3 study; 3 primary completions in the next 12 months. Compare ImmunityBio, Merck and Pfizer here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BCG VaccineRecent, repeated
Evidence
  • NCT07424287 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “BCG for Injection” · registered Feb 2026
  • NCT07122414 · Suzhou Forlong Biotechnology Co., Ltd · Phase 2 · live · background · “FL115+BCG” · registered Jul 2025
  • NCT03519256 · Bristol-Myers Squibb · Phase 2 · background · “BCG” · registered Apr 2018
  • NCT03528694 · AstraZeneca · Phase 3 · live · background · “Bacillus Calmette-Guerin (BCG)” · registered Feb 2018
  • NCT03022825 · ImmunityBio, Inc. · Phase 3 · live · background · “N-803 and BCG” · registered Jan 2017
Chongqing Zhifei Biological Products Co., Ltd.25% of its industry studies22 studies
GemcitabineRecent, repeated
Evidence
  • NCT07424287 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection” · registered Feb 2026
  • NCT06919965 · Johnson & Johnson · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2025
  • NCT06319820 · Johnson & Johnson · Phase 3 · live · comparator · “Gemcitabine” · registered Mar 2024
  • NCT06211764 · Johnson & Johnson · Phase 3 · live · comparator · “Gemcitabine” · registered Jan 2024
  • NCT04172675 · Johnson & Johnson · Phase 2 · standard-care · “Investigator Choice (Gemcitabine)” · registered Nov 2019
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed24 studies
MitomycinRecent, repeated
Evidence
  • NCT07424287 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Mitomycin for Injection” · registered Feb 2026
  • NCT06919965 · Johnson & Johnson · Phase 3 · live · comparator · “Mitomycin C” · registered Apr 2025
  • NCT06319820 · Johnson & Johnson · Phase 3 · live · comparator · “MMC” · registered Mar 2024
  • NCT06211764 · Johnson & Johnson · Phase 3 · live · comparator · “Mitomycin C” · registered Jan 2024
  • NCT04172675 · Johnson & Johnson · Phase 2 · standard-care · “Investigator Choice (Mitomycin C)” · registered Nov 2019
UroGen Pharma Ltd.70% of its industry studies24 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Picibanil☆ Track1 live phase-3 study: NCT07480356Protara Therapeutics
Lyophilized Inactivated Group A Streptococcus TARA-002☆ Track1 live phase-3 study: NCT07480356Protara Therapeutics
Erdafitinib-releasing Intravesical System TAR-210☆ Track2 live phase-3 studies: NCT06319820, NCT06919965Johnson & Johnson
Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H☆ Track1 live phase-3 study: NCT07804056Hamlet Pharma AB
efserakefusp alfa☆ Track2 live phase-3 studies: NCT07726992, NCT07424287Jiangsu HengRui Medicine Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 21 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.BCG Vaccine, nogapendekin alfa inbakicept · ImmunityBio, Inc. · Phase 2 main aimNCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer — primary endpoint: Efficacy of Arms A and B at Month 3 and Month 6 · 20 enrolled
  • Nov 2026 est.dabogratinib · Tyra Biosciences, Inc · Phase 2 named, not the main aimNCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations — primary endpoint: Phase 1 Part A: To determine the maximum tolerated doses (MTD). · 310 enrolled
  • 10 Oct 2027 est.IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115 · Suzhou Forlong Biotechnology Co., Ltd · Phase 2 main aimstudied with BCG VaccineNCT07122414 A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer — primary endpoint: MTD · 80 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Non-Muscle Invasive Bladder Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 11 open · Antimitotic agents 7 open · Antibody-drug conjugates (ADCs) 5 open · Tyrosine kinase inhibitors (TKIs) 4 open · Immune checkpoint inhibitors 3 open

Coming up

44studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger. 3 (3%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 2 (2%) take healthy volunteers.

Recruiting studies that take each age, of 93
AgeWomenMen
102 (2%)2 (2%)
1890 (97%)91 (98%)
3092 (99%)93 (100%)
4092 (99%)93 (100%)
5092 (99%)93 (100%)
6592 (99%)93 (100%)
7592 (99%)93 (100%)
8583 (89%)84 (90%)

Across all 294 studies, recruiting or not: 4% stop at 75 or younger and <1% at 65; 5% take children; 0% are for women only and 1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Non-Muscle Invasive Bladder Neoplasms studies take

Of 24 phase 1 interventional studies under Non-Muscle Invasive Bladder Neoplasms, half reached primary completion within 43 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 143 mo19–61 · 24 studies——
Observational42 mo30–… · 29 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 294. Browse all 294 → or search them.